Protein-tyrosine Phosphatase α Regulates Stem Cell Factor-dependent c-Kit Activation and Migration of Mast Cells*

Received for publication, May 28, 2008, and in revised form, August 7, 2008. Published, JBC Papers in Press, August 25, 2008, DOI 10.1074/jbc.M804077200

Lionel A. Samayawardenha†§ and Catherine J. Pallen†§¶

From the Departments of †Pediatrics and §Pathology and Laboratory Medicine and the ¶Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia V5Z 4H4, Canada

The role of protein-tyrosine phosphatase α (PTPα) in mast cell function was investigated in tissues and cells from PTPα-deficient mice. Bone marrow-derived mast cells (BMMCs) lacking PTPα exhibit defective stem cell factor (SCF)-dependent polarization and migration. Investigation of the molecular basis for this reveals that SCF/c-Kit-stimulated activation of the Fyn tyrosine kinase is impaired in PTPα−/− BMMCs, with a consequent inhibition of site-specific c-Kit phosphorylation at tyrosines 567/569 and 719. Although c-Kit-mediated activation of phosphatidylinositol 3-kinase and Akt is unaffected, pro-tyrosines 567/569 and 719. Although c-Kit-mediated activation of phosphatidylinositol 3-kinase and Akt is unaffected, pro-tyrosines 567/569 and 719. Although c-Kit-mediated activation of phosphatidylinositol 3-kinase and Akt is unaffected, pro-tyrosines 567/569 and 719. Although c-Kit-mediated activation of phosphatidylinositol 3-kinase and Akt is unaffected, pro-

PTPα is a receptor-type protein-tyrosine phosphatase that is widely expressed in many cells and tissues including those of hematopoietic origin. It has a short, glycosylated extracellular region with no known ligand binding specificity, a single transmembrane spanning region, and an intracellular region containing two tandem catalytic domains (1). The generation of PTPα-deficient mice confirmed findings from PTPα overexpression studies that this phosphatase functions as a physiological regulator of Src family kinases (SFKs), catalyzing the dephosphorylation of the inhibitory C-terminal tyrosine residue of SFKs and activating them (2–5). Despite the widespread actions of SFKs in multiple cellular and biological processes, PTPα-null mice with reduced SFK activity are viable and have an overall normal appearance, suggesting that PTPα is likely one of several SFK regulators with tissue-, cell-, and/or signaling pathway-specific functions.

In keeping with PTPα being highly expressed in brain, several studies, many utilizing PTPα-null mice and cells, have revealed multiple cellular and/or physiological roles of this PTPα linked to nervous system development and function. These include regulating N-methyl-D-aspartate receptor phosphorylation and activity, long-term potentiation, and spatial memory (6–9); sciatic nerve myelination and voltage-gated potassium channel activation and phosphorylation (10, 11), migration of pyramidal neurons (6), and neuronal outgrowth and differentiation (3, 12–15). In addition, PTPα regulates integrin-stimulated cell migration (4, 16), T cell activation (17), and mitosis (18). In the absence of an identified ligand for PTPα, it appears that PTPα-mediated SFK activation is often linked to activation of certain receptors by their ligands. Indeed, PTPα physically associates with receptors that themselves lack enzymatic activity, including the neural cell adhesion molecules contactin and NCAM140 (12, 19), and integrin α, (20), and in this way may mediate ligand-induced SFK activation.

Cells of the immune system have multiple well defined signaling pathways that are initiated by receptor-mediated SFK-dependent events. A role for PTPα has been recently demonstrated in T cell receptor-mediated activation and CD44-mediated spreading of T cells (17, 21). To further our understanding of PTPα functions in immune cells, and also to query whether PTPα regulates SFK-dependent signaling that is initiated by a receptor with intrinsic enzymatic activity, we have investigated the role of PTPα in mast cells, and specifically in regulating signaling by the receptor-tyrosine kinase c-Kit.

Mast cells play key roles in innate and adaptive immune responses, extending from their actions as regulators of allergic inflammation to roles in host defense, immunological tolerance and autoimmune diseases, atherosclerosis, and cancer (22–24). Mast cell progenitors leave the bone marrow and migrate to various connective and mucosal locations where they complete their development and give rise to mature populations with tissue-specific functions (25, 26). Many mast cell processes such as migration, proliferation, survival, differentiation, and maturation are regulated by stem cell factor (SCF) (27). This ligand binds to and activates c-Kit, a member of the type III subclass of receptor tyrosine kinases. Besides its role in normal mast cell development and function, aberrant c-Kit signaling, due to c-Kit overexpression, or autocrine or mutational activation, is linked to mastocytosis and some human tumors such as...
acute myeloid leukemia and gastrointestinal stromal tumors (28–30). The development of therapeutics targeted to c-Kit or to c-Kit regulators and signaling effectors is being actively pursued for the treatment of these diseases.

The earliest events in c-Kit-mediated signaling are the SCF-induced trans-autophosphorylation of receptor dimers, creating phosphotyrosyl binding sites for several signaling molecules. Extensive mutation/function analyses of c-Kit have identified phosphotyrosyl tyrosine residues and their binding partners that are critical in SCF-dependent cell events and processes. For example, three tyrosine residues, Tyr567, Tyr569, and Tyr719, are responsible for c-Kit-mediated cell migration, with Tyr567/569 playing a more critical role in this process (31, 32). Phospho-Tyr567/569 is a binding site for the SFKs Fyn (33, 34) and Lyn (35, 36), and recruitment of these kinases by c-Kit is believed to effect their activation. In addition, the phosphatases Shp1 and Shp2, as well as Chk, Cbl, Shc, and APS can associate with phospho-Tyr567/569, phospho-Tyr719 recruits phosphatidylinositol 3-kinase (PI3K), and other phosphorylated tyrosine residues bind to proteins such as Grb2, Grb7, and phospholipase γ (37, 38). The complexes of phosphotyrosyl-c-Kit and associated molecules activate multiple downstream signaling events that determine mast cell responses. Critical roles for the c-Kit upstream effectors Lyn, Lyn, or the p85 subunit of class IA PI3K are apparent from the multiple defective SCF-stimulated signaling events and responses of mast cells lacking these molecules (39–43).

We find that bone marrow-derived mast cells (BMMCs) from PTPα−/− mice have profound defects in c-Kit-dependent migration, and c-Kit signaling is impaired at multiple points. Notable early defects involve defective Fyn activation and c-Kit tyrosine phosphorylation that impinge on Gab2-mediated downstream events such as Rac/JNK activation, whereas PI3K/Akt signaling from c-Kit is unaffected. Also, tissue-resident mast cell populations are altered in PTPα-null mice. Thus, the cooperative interaction of two receptors with opposing enzymatic activities, the receptor tyrosine kinase c-Kit and the RPTP PTPα, is required for SCF-stimulated SFK activation and signaling, and for mast cell migration.

**EXPERIMENTAL PROCEDURES**

**Animals**—PTPα−/− and wild-type (PTPα+/+) mice (5) were maintained as an advanced intercross line (129Sv/Ev x Black Swiss, 50:50 mixed background) and housed under specific pathogen-free conditions. Animal care and use followed the guidelines of the University of British Columbia and the Canadian Council on Animal Care.

**Antibodies and Reagents**—The following antibodies were used: c-Kit, phospho-Tyr719, c-Kit, phospho-Ser473-Akt, Akt, phospho-Tyr407-Lyn, Lyn, Fyn, phospho-ERK1/2, ERK1/2, phospho-Thr180/183-p38, p38, phospho-JNK, JNK, phospho-Tyr542-Shp2, phospho-Tyr452-Gab2, phospho-PAK (Cell Signaling Technology); Lyn, Shp2 (BD Biosciences); phospho-Tyr567/569, c-Kit, Shc, Vav, PAK, actin (Santa Cruz Biotechnology); phosphotyrosine (4G10), Gab2, p85, Rac2 (Upstate Biotechnology); phospho-Tyr299-Src (Biosource), Rac1 (Stressgen), Cdc42 (Chemicon), dinitrophenyl-IgE (Sigma), IgE-fluorescein isothiocyanate, c-Kit-phycocerythrin (PE), rat IgG1-fluorescein isothiocyanate, rat IgG2a-PE (Caltag Labs). Alexa Fluor 488-conjugated phalloidin was purchased from Molecular Probes. Horseradish peroxidase-conjugated goat anti-mouse antibody and horseradish peroxidase-conjugated goat anti-rabbit antibody were from Sigma. Recombinant SCF, IL-3, and IL-6 were purchased from PeproTech, Inc. SU6656 was from EMD Biosciences.

**Analysis of Tissue Resident Mast Cell Populations**—Paraformaldehyde-fixed skin samples from mouse ears and backs, and sections from stomachs, were stained with toluidine blue and counted. Peritoneal cells were recovered by lavage and kept at 37 °C overnight in BMMC medium (Iscove’s modified Dulbecco’s medium with 10% fetal bovine serum, 1% antimicrobial-antimycotic, 1 mM sodium pyruvate, 1% non-essential amino acids, 50 μM α-mercaptoethanol) containing 100 ng/ml dinitrophenyl-IgE. Cells were washed in phosphate-buffered saline and labeled with anti-IgE-fluorescein isothiocyanate and anti-kit, or with the isotype controls rat IgG1-fluorescein isothiocyanate and rat IgG2a-PE, and analyzed by flow cytometry. Mast cell (double labeled for FceRI and c-Kit) numbers were determined and their percentage of the total cells was calculated. Alternatively, cells from peritoneal lavages were washed and resuspended in cold phosphate-buffered saline, fixed in 4% paraformaldehyde at 4 °C overnight, and then stained with toluidine blue for mast cell counting.

**Isolation, Culture, and Characterization of BMMCs**—Bone marrow from femurs of 4–8-week-old PTPα+/+ and PTPα−/− mice was placed in BMMC medium containing IL-3. The IL-3 sources were 3–5% conditioned medium from X63-IL-3 cells (kindly provided by Dr. A. Craig, Queens University) or from WEHI-3 cells (kindly provided by Dr. K. McNagny, University of British Columbia), or 10 ng/ml recombinant mouse IL-3 BMMCs were enriched by discarding adherent cells. The isolated BMMCs were maintained in culture at 0.5–1.0 × 10⁶ cells/ml for 4–6 weeks. Before use, BMMC purity was routinely monitored by flow cytometry to detect c-Kit and FceRI.

**Plasmid Constructs and BMMC Infection**—PTPα cDNA was cloned into BglII and Xhol sites in pMSCVpurom vector (Clontech Laboratories, Inc.) and the insert verified by sequencing. The PT67 murine stem cell virus (MSCV) packaging cell line was transfected with pMSCVpuro or pMCSVpuRO-PTPα plasmids using Lipofectamine, and retroviruses collected 48 h later and filtered (0.2 μm pore). Bone marrow cells from PTPα-null mice were cultured in BMMC medium containing 10 ng/ml IL-6, 10 ng/ml IL-3, and 50 ng/ml SCF for 4 days. The bone marrow progenitors were incubated twice with retroviral supernatants in media with 8 μg/ml Polybrene for 24 h. Cells were cultured in BMMC media for 2 days, followed by selection with 1 μg/ml puromycin for 3 weeks, and analyzed by flow cytometry to confirm the surface expression of c-Kit and FceRI prior to use.

**BMMC Spreading, Polarization, and Migration**—BMMCs were placed in starvation medium (BMMC medium without IL-3) overnight. To assess spreading and polarization, the cells were plated on fibronectin (20 μg/ml)-coated glass coverslips in Iscove’s modified Dulbecco’s medium with 0.1% bovine serum albumin with or without 50 ng/ml SCF. After 15 or 60 min, the
cells were fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton X-100 in phosphate-buffered saline, labeled with Alexa-Fluor 488-conjugated phalloidin and 4',6-diamidino-2-phenylindole, and visualized using a Leica DM4000 B microscope. Cell length and area were quantified using Open Lab software. For migration assays, the starved BMMCs were resuspended in Iscove’s modified Dulbecco’s medium with 0.25% sodium deoxycholate, 10% glycerol, 25 mM NaF, 10 μM MgCl₂, 1 mM EDTA, 1 mM sodium orthovanadate, 10 μg/ml aprotinin, 10 μg/ml leupeptin. Lysates were incubated for 60 min at 4 °C on a rotator with glutathione-S-transferase-p21-binding domain (GST-PBD) fusion protein pre-bound to glutathione-Sepharose beads. GST-PBD-bound complexes were recovered by centrifugation followed by three washes with lysis buffer.

Data Analysis—Cell polarization and migration data and that obtained by densitometric quantification of immunoblots were statistically analyzed using single factor analysis of variance and/or the Student’s t test.

RESULTS

Impaired SCF-induced Migration of PTPα−/− BMMCs—BMMC progenitor cells were prepared and cultured in the presence of conditioned medium containing the cytokine IL-3. After 4 weeks of culture, FACS analyses determined that >97% of the PTPα−/− and wild-type cells (n = 10 independent cultures/genotype) were positive for both c-Kit and FcεRI, markers of mature mast cells (data not shown). Thus PTPα is not required for IL-3-induced mast cell maturation ex vivo.

A Transwell chemotaxis assay was used to investigate the requirement for PTPα in mast cell migration that is mediated by signaling by the SCF receptor (c-Kit) and integrins (44). Compared with wild-type BMMCs, a significant reduction (~80%) was observed in the number of PTPα-deficient BMMCs that migrated to the underside of the membrane (Fig. 1, A and B), and into the SCF-containing medium in the bottom chambers of the wells (Fig. 1C). In the absence of SCF, very few BMMCs of either genotype migrated to the underside of the membrane (PTPα+/+, 1.7 ± 0.8/field; PTPα−/−, 2.1 ± 1.2/field), and no cells were found in the medium of the bottom chambers (data not shown), indicating that the SCF receptor, c-Kit, was functionally involved in mediating the above responses. To confirm that the absence of PTPα was the underlying cause of this migration defect, PTPα was re-expressed in the PTPα-null BMMCs by retroviral (MSCV) infection, to a level equivalent to 138% of that in wild-type BMMCs. This completely restored the SCF-dependent migration ability of the mast cells, whereas infection with retrovirus expressing a control “empty” vector was unable to rescue impaired migration of PTPα−/− BMMCs (Fig. 1, A–C).

PTPα−/− BMMCs Exhibit Delayed Spreading and Polarization—In view of the migration defect of PTPα−/− BMMCs, their ability to carry out several cellular events associated with cell migration was investigated. BMMCs were
PTPα in c-Kit Signaling and Mast Cell Migration

FIGURE 2. Delayed SCF-induced spreading and polarization of PTPα−/− BMMCs. PTPα+/+ (+/+) and PTPα−/− (−/−) BMMCs were plated on fibronectin-coated coverslips in medium with 50 ng/ml SCF. After 15 and 60 min, cells were fixed and stained with phalloidin, and morphology and associated parameters were scored. A, representative photographs of cells. Arrows indicate directionality of polarized cells. Scale bar, 10 μm. B, percentages (mean ± S.D.) of round or spread cells at 15 min (n = 30). C, percentages (mean ± S.D.) of round, spread, or polarized cells at 60 min (n = 30). D, cell perimeter; E, cell length at the longest axis; and F, cell area were measured at 15 and 60 min and the mean ± S.E. are shown (n = 200). In B-F, data were collected from three independent experiments. White bars represent PTPα+/+ BMMCs and black bars represent PTPα−/− BMMCs, and asterisks depict a significant difference (p < 0.05) between cell types.

FIGURE 3. SCF-stimulated tyrosine phosphorylation of BMMC proteins and c-Kit in wild-type and PTPα−/− cells. Wild-type (PTPα+/+) and PTPα−/− BMMCs were left untreated (0) or stimulated with SCF for 5, 15, and 30 min. A, cell lysates were probed for phosphotyrosine (P-Tyr), c-Kit, PTPα, and actin as indicated. B, c-Kit was immuno precipitated and probed for phosphotyrosine and c-Kit. The immunoblots shown in A and B are representative of results of 6–8 independent experiments. C, cell lysates without or with 5 min SCF treatment were probed with phosphosite-specific c-Kit antibodies and anti-c-Kit antibody. Results from three experiments were quantified and are shown in the graph. Bars represent the mean ± S.D. (gray, PTPα+/+ cells; black, PTPα−/− cells). The asterisks depict a significant difference (p < 0.01).

PTPα-null BMMCs Have Site-specific Alterations in SCF-stimulated c-Kit Tyrosine Phosphorylation—Because impaired SCF-dependent...
migration of PTPα−/− BMMCs was observed, we investigated whether SCF-stimulated signaling events in BMMCs were affected by the absence of PTPα. No obvious differences in protein tyrosine phosphorylation profiles were apparent between wild-type and PTPα−/− cells following SCF stimulation for up to 30 min (Fig. 3A). Likewise, SCF-induced tyrosine phosphorylation of c-Kit appeared normal in BMMCs lacking PTPα (Fig. 3B). Despite this, probing BMMC lysates with phosphosite-specific antibodies to phospho-Tyr567/569 and phospho-Tyr719 of c-Kit revealed significantly reduced (by 35%) phosphorylation at these sites after 5 min of stimulation with SCF (Fig. 3C), and in other experiments similar reductions were detected after 15 and 30 min stimulation (data not shown). These phosphoryrosine residues are binding sites for c-Kit effector signaling molecules, including the binding of the SFKs Fyn and Lyn to phospho-Tyr567/569 and the recruitment of PI3K to phospho-Tyr719 (33–36, 45). The lowered phosphorylation of these sites in the absence of PTPα suggests that critical downstream signaling events may be impaired in PTPα−/− BMMCs.

**Defective SCF-induced Dephosphorylation of Fyn in PTPα−/− BMMCs**—The SFKs Lyn and Fyn are activated early in c-Kit signaling, and Fyn has specifically been implicated in SCF/c-Kit-induced, integrin-mediated BMMC spreading and polarization, whereas both Fyn and Lyn play roles in SCF/c-Kit-induced BMMC chemotaxis (39, 40, 42). Furthermore, PTPα is a positive regulator of SFKs, catalyzing their activation through dephosphorylation of the conserved regulatory C-terminal tyrosine residue (1). Therefore the tyrosine phosphorylation status of Fyn and Lyn in SCF-stimulated BMMCs was examined. In wild-type BMMCs, SCF treatment resulted in the rapid (by 5 min) dephosphorylation of Tyr528 of Fyn, indicative of Fyn activation (Fig. 4, A and B). The reduced phosphorylation of Fyn Tyr528 was maintained at 15 min, with full rephosphorylation occurring by 30 min. However, in PTPα−/− BMMCs, no dephosphorylation of Fyn was observed in response to SCF (Fig. 4, A and B). In contrast to Fyn, Lyn phosphorylation at the regulatory C-terminal tyrosine residue, as assessed by immunoblotting with antibody directed to phospho-Tyr527 of Src, was not altered upon SCF stimulation of wild-type or PTPα−/− BMMCs (Fig. 4, C and D). This was also the case upon probing Lyn immunoprecipitates with anti-phosphotyrosine antibody or with anti-phospho-Tyr567 of Lyn (data not shown). Thus we were unable to determine whether PTPα affected Lyn activity in unstimulated or SCF-stimulated BMMCs. However, the analysis of Lyn phosphorylation demonstrates that PTPα is required for SCF-stimulated Fyn dephosphorylation and the consequent activation of this SFK.

To determine whether defective SFK activity in PTPα-null BMMCs is a potential basis for the reduced SCF-stimulated phosphorylation of c-Kit Tyr567/569 and Tyr719, the phosphorylation of these sites was examined after treatment of BMMCs with the SFK inhibitor SU6656. In both wild-type and PTPα−/−
PTPα in c-Kit Signaling and Mast Cell Migration

BMMCs, this compound reduced the SCF-induced tyrosine phosphorylation of a band that co-migrated with c-Kit and of some other proteins of ~70–80 kDa (Fig. 4E). SU6656 also inhibited the phosphorylation of Tyr567/569 and Tyr719 (Fig. 4F). In PTPα−/− BMMCs, SU6656 treatment further inhibited the already reduced phosphorylation of these residues, likely because PTPα-null cells have basal SFK activity that is lost upon SU6656 treatment. These results indicate that SFK activity is indeed required for complete c-Kit phosphorylation, and suggests that the lower phosphorylation of specific tyrosine residues of c-Kit in PTPα−/− BMMCs is a consequence of reduced SFK activity, including that of Fyn.

**PI3K Signaling Is Not Markedly Altered in PTPα−/− BMMCs**—PTPα binds to phospho-Tyr719 of c-Kit to initiate downstream signaling, including Akt activation (37, 38). Other mechanisms of c-Kit signaling can also activate PI3K, because both PI3K and Akt are activated by c-Kit lacking Tyr719 but with intact Tyr567/569 residues (32). We found that binding of the p85 subunit of PI3K to c-Kit was enhanced upon SCF stimulation of wild-type and PTPα−/− BMMCs and that this binding was sometimes (Fig. 5A) but not always somewhat reduced in cells lacking PTPα. Likewise, Akt activation was not significantly different between SCF-stimulated wild-type and PTPα−/− BMMCs (Fig. 5B). Thus, c-Kit-mediated PI3K/Akt signaling is not dramatically affected in BMMCs lacking PTPα.

**SCF-induced MAPK Activation Is Reduced and Less Sustained in BMMCs Lacking PTPα**—Fyn and Lyn have been implicated in SCF-stimulated activation of ERK1/2, JNK, and p38 in mast cells (31, 32, 34, 39, 41). To determine whether PTPα plays a role in the activation of these MAPKs, their kinetics of activation, as reflected by site-specific changes in their phosphorylation, were compared between wild-type and PTPα-deficient BMMCs. Defects were observed in the SCF-mediated activation profiles of all of these MAPKs in PTPα-deficient BMMCs. At all times following SCF stimulation, ERK1/2 activation was reduced in cells lacking PTPα (Fig. 6A). JNK and p38 activation were also reduced in SCF-stimulated PTPα−/− cells (Fig. 6, B and C). Together, these results indicate that PTPα is required for the optimal activity of multiple downstream MAPK effectors of c-Kit signaling.

**Defective Rho GTPase Activation and Signaling in PTPα−/− BMMCs**—The Rho family of small GTPases, including the members Rho, Rac, and Cdc42, play critical roles in the migration of non-hematopoietic cells. Rac has specifically been demonstrated to mediate c-Kit signaling, as BMMCs lacking the hematopoietic cell-specific Rac2 exhibit reduced migration in response to SCF stimulation (44), Rac1 activation occurs in SCF-treated BMMCs in an SKF- and Gab2-dependent manner (46), and Rac1 and Rac2 activation is defective in Fyn-null BMMCs (40). We found that Rac1, Rac2, and Cdc42 all underwent SCF-induced activation in wild-type BMMCs, with peak activation observed between 5 and 15 min (Fig. 7, A–C). In PTPα-null BMMCs, the activation of these GTPases was delayed, with either no significant activation (Rac1, Rac2) or reduced activation (Cdc42) detected at 5 min post-SCF stimulation, and a consistent reduction in Rac1, Rac2, and Cdc42 activation that persisted from 15 to 30 min (Fig. 7, A–C). In accord with these findings, SCF-induced activation of the Rac and

**FIGURE 5. SCF-stimulated PI3K signaling is not affected in PTPα−/− BMMCs.** Wild-type (PTPα+/+) and PTPα−/− BMMCs were left untreated (0) or stimulated with SCF for 5, 15, and 30 min as indicated. A, c-Kit immunoprecipitates were probed for phosphotyrosine (P-Tyr), p85, and c-Kit. The blot shown is representative of three experiments, but no change in p85 binding to c-Kit was observed in two other experiments (not shown). B, cell lysates were probed for phospho-Ser473-Akt and Akt. Quantified results from three such experiments are shown in the graph. The bars represent the mean ± S.D. and the asterisks depict a significant difference (p < 0.01) between PTPα+/+ (gray bars) and PTPα−/− (black bars) BMMCs.

**FIGURE 6. SCF-induced MAPK activation is defective in PTPα−/− BMMCs.** Wild-type (PTPα+/+) and PTPα−/− BMMCs were left untreated (0) or stimulated with SCF for 5, 15, and 30 min. Lysates were probed for phospho-ERK1/2 and ERK1/2 (A), phospho-JNK and JNK (B), and phospho-p38 and p38 (C). The results from several experiments (ERK1/2, JNK, p38, n = 3) were quantified by densitometry, and the mean ± S.D. are shown in the graphs. Asterisks indicate a significant difference (p < 0.05) between wild-type (gray bars) and PTPα−/− (black bars) cells.
PTPα in c-Kit Signaling and Mast Cell Migration

We detected no increase in PAK phosphorylation at 5 min and reduced PAK phosphorylation at 15 and 30 min of SCF treatment of PTPα−/− cells (Fig. 7D). The SCF-induced activation of Vav (47), an upstream activator of Rac, was also significantly reduced at 15 and 30 min in PTPα−/− cells (Fig. 7E).

Gab2 and Shp2 Phosphorylation Is Impaired in SCF-stimulated PTPα−/− BMMCs—Shc binds to phospho-Tyr567 of activated c-Kit and is tyrosine phosphorylated by a non-SFK-type kinase (33, 46). This promotes the association of Shc with Grb2, and via Grb2 with Gab2. The c-Kit-associated Gab2 is tyrosine phosphorylated by SFKs, allowing the recruitment and phosphorylation of Shp2 that is necessary for downstream activation of Rac/JNK (46). We therefore examined whether SCF-stimulated Gab2 phosphorylation is affected in the absence of PTPα. In wild-type BMMCs, SCF-induced phosphorylation of Gab2 at Tyr452 was detectable at 5 and 15 min and disappeared by 30 min. However, in PTPα-null BMMCs, no phosphorylation of Gab2 at this site was observed at any time up to 30 min of SCF treatment (Fig. 8A). Shp2 is activated by tyrosine phosphorylation, although the mechanism by which Gab2-associated Shp2 signals to Rac/JNK is unknown. SCF-stimulated Shp2 phosphorylation was also reduced in PTPα-null BMMCs, as was its association with Gab2 (Fig. 8B). The above results indicate that SCF-stimulated Gab2 phosphorylation is mediated by PTPα, and that defective Gab2/Shp2 phosphorylation and signaling in SCF-stimulated PTPα−/− BMMCs could result in the impaired Rac and JNK activation observed in these cells.

Re-expression of PTPα Rescues c-Kit Signaling Defects—PTPα−/− BMMCs were infected with retrovirus expressing PTPα or a control “empty” vector (Fig. 9A). The re-expression of PTPα (to 147% of the level in wild-type BMMCs) restored SCF-induced c-Kit phosphorylation at Tyr567/569 and Tyr719 to levels observed in wild-type BMMCs, whereas PTPα−/− BMMCs infected with virus containing the empty vector still exhibited reduced c-Kit phosphorylation at these sites (Fig. 9B). The SCF-stimulated phosphorylation and activation of the downstream signaling molecules ERK1/2 and p38 (Fig. 9C) were also restored to normal levels in PTPα−/− BMMCs upon PTPα re-expression, confirming that the c-Kit signaling defects observed in the PTPα-null cells were indeed entirely due to the lack of this receptor phosphatase.

Altered Tissue Distribution of Mast Cells in PTPα−/− Mice—We investigated whether the absence of PTPα affected mast cell populations in specific tissues. No difference in mast cell...
PTPα in c-Kit Signaling and Mast Cell Migration

FIGURE 9. Restoring PTPα expression in PTPα−/− BMMCs rescues c-Kit phosphorylation and MAPK activation defects. PTPα+/+ and PTPα−/− BMMCs, and PTPα−/− BMMCs that had been infected with MSCV bearing empty vector (MSCV) or a PTPα expression vector (MSCV-PTPα) were left unstimulated or treated with SCF for the indicated times (min) and lysed. A, unstimulated lysates were probed for PTPα and actin. B, lysates were probed for phospho-Tyr567/569 and phospho-Tyr719 of c-Kit, and for c-Kit. The signals were quantified from this and another independent experiment and are shown under the autoradiographs as % phosphorylation relative to that in wild-type cells (taken as 100%). C, lysates were probed for phospho-ERK and ERK, and phospho-p38 and p38. Quantified signals from this and another independent experiment were averaged, and are shown under the autoradiographs as % phosphorylation relative to that in wild-type cells (taken as 100% at 5 min). White bars, wild-type BMMCs; black bars, PTPα-null BMMCs with MSCV empty vector; gray bars, PTPα-null BMMCs with MSCV expressing PTPα. Due to the high signals detected at 5 min versus the much lower signals at later time points, quantification of the 5-min signals was made at a non-linear exposure and under-represents differences between the cell types.

number was found in the dermis of back skin, but mast cell numbers were significantly reduced in the hypodermis of the back skin and in the ears of PTPα-deficient mice compared with wild-type mice (Fig. 10, A–C). Peritoneal cells were collected by lavage, and FACS analyzed for c-Kit- and FceRI-positive mast cells. Although total peritoneal cell numbers did not differ between genotypes, a striking 2-fold increase in the absolute number of mast cells was found in the PTPα−/− mice (Fig. 10D). Similar results were obtained by counting toluidine blue-positive mast cells and total cells collected from peritoneal lavages (data not shown). The same alterations were found in these tissues and for peritoneal mast cell percentages of wild-type and PTPα-null C57Bl6 mice (recently obtained after 10 generations of backcrossing the 129SvEv PTPα−/− animals) (data not shown), indicating that differences in tissue mast cell numbers are due to the ablation of PTPα and not to the mixed genetic background of the 129SvEv x Black Swiss mice. As the above represent connective tissue-type mast cells, we also examined mast cell numbers in the stomach mucosa but detected no difference in mucosal mast cell numbers between genotype (Fig. 10E). However, submucosal mast cells (usually considered as connective tissue mast cells) were significantly reduced in the PTPα−/− mice (Fig. 10F).

DISCUSSION

This study has identified PTPα as a critical determinant of the ability of mast cells to migrate and polarize in response to the c-Kit ligand SCF. PTPα regulates integrin signaling and migration in fibroblasts, however, the minimal migration of BMMCs that is observed upon integrin stimulation alone coupled with the strong dependence of mast cell migration on SCF prompted us to investigate the mechanisms of PTPα regulation of SCF/c-Kit signaling in BMMCs.

We demonstrate that PTPα plays an important role in immediate events triggered upon binding of SCF to c-Kit, as two key early changes, c-Kit phosphorylation and SFK activation, are impaired in the absence of PTPα. In PTPα−/− BMMCs there is reduced phosphorylation of c-Kit at Tyr567/569 and Tyr719, and defective activation of Fyn. Although Fyn-dependent phosphorylation of c-Kit at specific sites has not been examined, the overall tyrosine phosphorylation of c-Kit is unaffected in Fyn-deficient BMMCs (39), and this is similar to our observations in PTPα−/− BMMCs. Total and site-specific SCF-stimulated c-Kit tyrosine phosphorylation is reduced in Lyn-deficient BMMCs (41). SCF-stimulated Lyn phosphorylation/activation was not detectably altered in the absence of PTPα. However, neither did we observe altered Lyn phosphorylation/activation in SCF-treated wild-type BMMCs, and thus we are unable to draw any conclusions about the PTPα-mediated regulation of Lyn in c-Kit signaling. We found that phosphorylation of c-Kit at Tyr567/569 and Tyr719 is also reduced in BMMCs treated with the SFK inhibitor SU6656, indicating that the loss of PTPα-mediated Fyn activation, and perhaps that of other SFKs, is likely the critical defect underlying the reduced site-specific phosphorylation of c-Kit in PTPα-null BMMCs.

Despite reduced phosphorylation of c-Kit at its PI3K binding site, Tyr719, PI3K/Akt signaling was not affected in PTPα−/− BMMCs. In other studies, SCF-treated Fyn-null or Lyn-null BMMCs likewise did not exhibit altered binding of the p85 subunit of PI3K to c-Kit nor reduced Akt activation, although reduced phosphorylation of c-Kit at both Tyr567/569 and Tyr719 was observed in the latter cell type (39, 41). Because either of these important c-Kit phosphorylation sites can mediate PI3K and Akt activation in the absence of the other site (32), it appears that the partial phosphorylation of both sites in PTPα-null BMMCs (as in the Lyn-null cells) is sufficient for SCF-stimulated PI3K/Akt signaling.

However, in contrast to PI3K/Akt signaling, the SCF-induced activation of several other signaling molecules was defective in the absence of PTPα, including the scaffolding molecule Gab2. Gab2 functions downstream of SFK-mediated c-Kit sig-
naling, as the mutation of Tyr\(^{567}\) inhibits Gab2 tyrosine phosphorylation and association with c-Kit, and inhibition of SFKs strongly reduces SCF-induced Gab2 tyrosine phosphorylation (46). It has been proposed that, upon recruitment to c-Kit via Shc/Grb2 binding, Gab2 is phosphorylated by c-Kit-associated SFKs (46). Our finding that SCF-stimulated Gab2 tyrosine phosphorylation is abrogated in PTP\(\alpha^{-/-}\) BMMCs that have impaired Fyn activity is consistent with this, and place PTP\(\alpha\) as an upstream player in signaling from c-Kit to Gab2, with PTP\(\alpha\) functioning in conjunction with c-Kit to stimulate Fyn activity.

Previous studies have found that c-Kit Tyr\(^{567/569}\), Fyn, and Gab2 are involved in the SCF-dependent activation of Rac/JNK signaling, and of ERK1/2 and p38. Mutation of the c-Kit Tyr\(^{567/569}\) SFK binding site reduces Rac and JNK activation, and mutation of Tyr\(^{567}\) reduces activation of p38 and the ERK1/2 activating kinase mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) 1/2 (31, 34). Restoration of Tyr\(^{567/569}\) to c-Kit devoid of other major sites of tyrosine phosphorylation rescues ligand-stimulated Fyn, Rac, JNK, and ERK1/2 activation (32). In addition, mast cells lacking Fyn show defective activation of Rac1, Rac2, JNK, and p38 (39, 40), and those lacking Gab2 show defective activation of Rac1, Rac2, JNK, and ERK (46, 48). Overall, there is strong evidence for SFK signaling from c-Kit to Gab2, resulting in the downstream activation of Rac/JNK, p38, and ERK1/2. Our studies with PTP\(\alpha^{-/-}\) BMMCs indicate that PTP\(\alpha\) is required for effective SCF-induced activation of Rac1 and -2, and of the MAPKs JNK, p38, and ERK1/2. Our studies with PTP\(\alpha^{-/-}\) BMMCs indicate that PTP\(\alpha\) is required for effective SCF-induced activation of Rac1 and -2, and of the MAPKs JNK, p38, and ERK1/2, likely as a consequence of the action of PTP\(\alpha\) as an activator of Fyn, and at least for some of these events, of Fyn-Gab2 signaling. We have also demonstrated that PTP\(\alpha\) plays a role in SCF-induced activation of Vav, PAK, and Cdc42, proteins that can function as intermediates in these signaling pathways.

SFKs are critical for mast cell migration, as expression of the SFK inhibitory kinase Csk inhibits SCF-induced migration (31). Fyn-null BMMCs exhibit defective SCF-induced spreading and lamellipodia formation that is not observed in Lyn-null BMMCs (39, 40, 42). The impaired SCF-induced spreading, polarization, and migration of PTP\(\alpha^{-/-}\) BMMCs are in accord with the defective Fyn activation observed in these cells. Our results indicate that PTP\(\alpha\) is specifically required for the activation of a Fyn-based arm (Fyn/Gab2/Shp2/Vav/PAK/Rac/JNK) of c-Kit-mediated signaling that mediates mast cell migration and chemotaxis. The impaired c-Kit-dependent motility of PTP\(\alpha^{-/-}\) BMMCs may be manifested in the altered tissue resident mast cell numbers that we observe in PTP\(\alpha\)-null mice.
profound, on mast cell tissue populations. Mice with c-Kit mutations of Tyr<sup>567</sup>, Tyr<sup>567→569</sup>, or Tyr<sup>719</sup>, or deficient in Gab2 or p85α of class IA PI3K, exhibit reduced or absent mast cells in skin, peritoneum, and/or stomach mucosa and other gastrointestinal regions (43, 46, 48–50). Fyn-null mice have unaltered numbers of skin mast cells (51), whereas Lyn-null mice are unique in having 2–3-fold more skin and peritoneal mast cells (51, 52). However, none of these mutant mice share the phenotype of PTPα-null mice where some tissues exhibit reduced mast cell populations (hypodermis, ear, and stomach submucosa) but elevated mast cell numbers are present at another site, the peritoneum. Although the basis of this differential effect of ablating PTPα is unknown, we speculate that besides migration, other PTPα-dependent events in mast cell proliferation, survival, development, and/or maturation could affect mast cell populations in tissue-specific manners. Furthermore, additional or alternative actions of PTPα, as a plasma membrane mast cell receptor, might regulate other (non-c-Kit) signaling pathways in tissue- or developmentally specific manners that differentially combine with its actions on c-Kit signaling to determine mast cell populations.

Collectively, our findings establish that PTPα plays an upstream positive regulatory role in c-Kit signaling and BMMC migration, and regulates tissue mast cell populations in vivo, highlighting the importance of PTPα in the function of these immune cells. Specifically, PTPα mediates activation of the SFK Fyn in response to the c-Kit ligand SCF. As c-Kit and SFK inhibitors have shown therapeutic utility in the treatment of some forms of cancer (29, 53), our findings have implications for targeting PTPα as an additional or alternate strategy in the treatment of diseases that are associated with up-regulated SFK-dependent c-Kit signaling.

Acknowledgments—We are grateful to Dr. Andrew Craig of Queen’s University for the gift of X63-IL-3 cells and for helpful advice and critical reading of the manuscript. We also thank Darrell Bessette for comments on the manuscript, Dr. Kelly McNagy of the University of British Columbia for providing WEHI-3 cells, and Dr. Ed Manser of the Institute of Molecular and Cell Biology, Singapore, for pGEX-PBD. Maintenance of the PTPα<sup>+/−</sup> mouse colony by Dr. Jing Wang is gratefully acknowledged.

REFERENCES
1. Pallen, C. J. (2003) Curr. Top. Med. Chem. 3, 821–835
2. Zheng, X. M., Wang, Y., and Pallen, C. J. (1992) Nature 359, 336–339
3. den Hertog, J., Pals, C. E., Peppelenbosch, M. P., Tertoolen, L. G., de Laat, S. W., and Kruijver, W. (1993) EMBO J. 12, 3789–3798
4. Pallen, C. J., Williams, D. A., and Kapur, R. (2003) Cell Signal. 15, 103–109
5. Samayawardhena, L. A., Kapur, R., and Craig, A. W. (2007) Annu. Rev. Immunol. 25, 59–76
6. Sayed, B. A., Christy, A., Quirion, M. R., and Brown, M. A. (2008) Annu. Rev. Immunol. 26, 705–739
7. Kovanen, P. T. (2007) Immunol. Rev. 217, 105–122
8. Petrone, A., Battaglia, F., Wang, C., Dusa, A., Su, J., Zagzag, D., Bianchi, R., Casaccia-Bonnefil, P., Arancio, O., and Sap, J. (2003) EMBO J. 22, 359–378
9. Timokhina, I., Kissel, H., Stella, G., and Besmer, P. (1998) EMBO J. 17, 336–339
10. Fukao, T., Yamada, T., Takeuchi, T., Kadowaki, T., Hata Ji, J., and Koyasu, S. (2002) Nat. Immunol. 3, 611–616
11. Williams, D. A., and Kapur, R. (2003) Cell Mol. Life Sci. 60, 2391–2402
12. Sayed, B. A., Christy, A., Quirion, M. R., and Brown, M. A. (2008) Annu. Rev. Immunol. 26, 705–739
13. Brown, J. M., Wilson, T. M., and Metcalfe, D. D. (2008) Clin. Exp. Allergy 38, 4–18
14. Williams, D. A., and Kapur, R. (2003) Cell Mol. Life Sci. 60, 2391–2402
15. Liu, M., Harder, K. W., and Yu, X. M. (2002) Cell Signal. 14, 1035–1045
16. Zeng, L., Si, X., Yu, W. P., Le, H. T., Ng, K. P., Teng, R. M., Ryan, K., Wang, D. Z., Ponniah, S., and Pallen, C. J. (2003) J. Cell Biol. 161, 137–146
17. Maksumova, L., Le, H. T., Murakkhodjaev, F., Davidson, D., Veillette, A., and Pallen, C. J. (2005) J. Immunol. 175, 7947–7956
18. Zheng, X. M., and Shalloway, D. (2001) EMBO J. 20, 6037–6049
19. Zeng, L., D’Alessandri, L., Kalousek, M. B., Vaughan, L., and Pallen, C. J. (1999) J. Cell Biol. 147, 707–714
20. Okayama, Y., and Murak, K. (2006) J. Cell Biol. 174, 1411–1423
21. Hata, J., Kadowaki, T., Hata, J., and Koyasu, S. (2002) Nat. Immunol. 3, 611–616
22. Brown, J. M., Wilson, T. M., and Metcalfe, D. D. (2008) Clin. Exp. Allergy 38, 4–18
23. Kovanen, P. T. (2007) Immunol. Rev. 217, 105–122
24. Sayed, B. A., Christy, A., Quirion, M. R., and Brown, M. A. (2008) Annu. Rev. Immunol. 26, 705–739
25. Galili, S. L., Kalesnikoff, J., Grimald, M. A., Piliponsky, A. M., Williams, C. M., and Tsai, M. (2005) Annu. Rev. Immunol. 23, 749–786
26. Brown, J. M., Wilson, T. M., and Metcalfe, D. D. (2008) Mol. Biol. Cell. 217, 103–109
27. Brown, J. M., Wilson, T. M., and Metcalfe, D. D. (2008) Mol. Biol. Cell. 217, 103–109
47. Alai, M., Mui, A. L., Cutler, R. L., Bustelo, X. R., Barbacid, M., and Krystal, G. (1992) J. Biol. Chem. 267, 18021–18025
48. Nishida, K., Wang, L., Morii, E., Park, S. J., Narimatsu, M., Itoh, S., Yamashaki, S., Fujishima, M., Ishihara, K., Hibi, M., Kitamura, Y., and Hirano, T. (2002) Blood 99, 1866–1869
49. Agosti, V., Corbacioglu, S., Ehlers, I., Waskow, C., Sommer, G., Berrozpe, G., Kissel, H., Tucker, C. M., Manova, K., Moore, M. A., Rodewald, H. R., and Besmer, P. (2004) J. Exp. Med. 199, 867–878
50. Kimura, Y., Jones, N., Kluppel, M., Hirashima, M., Tachibana, K., Cohn, J. B., Wrana, J. L., Pawson, T., and Bernstein, A. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 6015–6020
51. Odom, S., Gomez, G., Kovarova, M., Furumoto, Y., Ryan, J. J., Wright, H. V., Gonzalez-Espinosa, C., Hibbs, M. L., Harder, K. W., and Rivera, J. (2004) J. Exp. Med. 199, 1491–1502
52. Hernandez-Hansen, V., Mackay, G. A., Lowell, C. A., Wilson, B. S., and Oliver, J. M. (2004) J. Leukocyte Biol. 75, 143–151
53. Apice, G., Milano, A., Bruni, G. S., Iaffaioli, R. V., and Caponigro, F. (2006) Rev. Recent Clin. Trials 1, 35–42